Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 23, 2025Scientific ReportsOpen Access

Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

GZGuihua ZhangSCShengya CaoCGChong Geng

Discussion

Loading...

Member takes

Overview

Single-cell and bulk transcriptomics highlights PRKD2's role in tumor stemness and axitinib sensitivity in multiple myeloma.

Key Points

  • Axitinib boosts apoptosis in PRKD2-overexpressing cells, suggesting therapeutic angles for intervention.
  • The study shows PRKD2 is linked to immune escape and clonal evolution, impacting multiple myeloma aggressiveness.
  • Bulk RNA-seq and single-cell transcriptomics reveal PRKD2's vital role in driving tumor stemness and progression.
  • Targeting PRKD2 may offer new strategies to combat high-risk multiple myeloma and improve patient outcomes.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68fa32a40df2e6cd2f7421b5https://doi.org/10.1038/s41598-025-20615-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell profiling uncovers PTPRG-driven stemness in malignant plasma cells and signatures of treatment failure in multiple myeloma2025
  2. 2Oncogenic ASPP2κ: A novel regulator of drug resistance and tumor progression in multiple myeloma2025
  3. 3KPNA2 enhances autophagy through activation of the non-canonical NF-κB signaling pathway, thereby promoting the induction of bortezomib resistance in multiple myeloma2025
  4. 4SKP2/CKS1B as a rational drug target in 1q21 amplified multiple myeloma.2025
  5. 5Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease2025